Clinical Trials
40 trialsTemozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
National Cancer Institute (NCI)
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Big Ten Cancer Research Consortium
Relapsed SCLC
VA Office of Research and Development
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
Jonsson Comprehensive Cancer Center
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Ohio State University Comprehensive Cancer Center
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
Nerviano Medical Sciences
TRIO-US L-07
Jonsson Comprehensive Cancer Center
An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
Columbia University
M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers
National Institutes of Health Clinical Center (CC)
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
BeiGene
IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer
Impact Therapeutics, Inc.
HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer
Shanghai Huilun Pharmaceutical Co., Ltd.
Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease
University of Colorado, Denver
Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy
Massachusetts General Hospital
Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer
Guangzhou Medical University
Temozolomide Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Non Small Cell Lung Cancer Brain Metastases
Taizhou Hospital
TeRes
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)
Merck Sharp & Dohme LLC
Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)
Merck Sharp & Dohme LLC
Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)
Merck Sharp & Dohme LLC
Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)
Merck Sharp & Dohme LLC
Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)
Merck Sharp & Dohme LLC
Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic
China Medical University, China
Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer
Chinese PLA General Hospital
Temozolomide as Maintenance Therapy in Small Cell Lung Cancer
Chinese PLA General Hospital
A Phase II Multi-center Pilot Study of Concurrent Temozolomide and Whole Brain Irradiation in Lung Cancer and Breast Cancer Patients With Brain Metastases
Far Eastern Memorial Hospital
Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer
Fox Chase Cancer Center
Temozolomide in Treating Patients With Metastatic Non-small Cell Lung Cancer
Case Comprehensive Cancer Center
QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC
Rutgers, The State University of New Jersey
Temozolomide in Treating Patients With Relapsed or Progressive Small Cell Lung Cancer
Fox Chase Cancer Center
Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases
Swiss Cancer Institute
CN-306
Tufts Medical Center
Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC
Tel-Aviv Sourasky Medical Center